OR WAIT null SECS
Sphere Fluidics has closed its latest investment round in which it raised US$2 million (approximately £1.5 million).
Sphere Fluidics, developer and manufacturer of single cell analysis and monoclonality assurance systems for biotherapeutic discovery and cell line development, has closed its latest investment round in which it raised $2 million (approximately £1.5 million).
Funding was secured from several investors that included Greenwood Way Capital, Oxford Technology, and Innovations EIS Fund and 24Haymarket, and will be used to grow operations and support sales of Sphere Fluidic’s Cyto-Mine single cell analysis system. The company is seeking to expand operations and sales capabilities across the United Kingdom and the United States and will open a new sales office on the West Coast of the US.
“We are pleased to see such a high level of interest in Sphere Fluidics and receive funding from several leading investors,” stated Frank F Craig PhD MBA, CEO, Sphere Fluidics, in a Jan. 29, 2019 press statement. “We are making further investment in automating and streamlining our manufacturing processes across our product range to extend our offering and to deliver our high-quality standards and service to more researchers working in biotherapeutic discovery and cell line development across the UK and US. We will be raising additional funds to expand these capabilities further.”
Source: Sphere Fluidics